

Supplementary data


Table 1. MiRNAs with altered expression in malignancy

| Tissue/tumor type | Increased expression | Decreased expression |
|---|--|---|
| Breast ^{21, 22} | miR-21, miR-29b-2 | miR-125b, miR-145 miR-10b, miR-155, miR-17-5p, miR-27b |
| Ovarian ^{23, 24} | miR-141, miR-200(a-c), miR-221 | let-7f, miR-140, miR-145, miR199a, miR-424 |
| Endometrial ²⁵⁻²⁷ | miR-103, miR-107, miR-185, miR-205, miR-210, miR-449 | miR-99b, miR-152, miR-193, miR-204, miR-221, let-7i |
| Glioblastoma ^{28, 29} | miR-221, miR-21 | miR-181a, miR-181b, miR-181c |
| Chronic lymphocytic leukemia ⁸ | | miR-15, miR-16 |
| Lymphoma ^{28, 30} | miR-155, miR-17-92cluster | miR-15a |
| Colorectal ^{9, 28-31} | miR-10a, miR-17-92 cluster, miR-20a, miR-24-1, miR-29b-2, miR-31 | miR-143, miR-145, let-7 |
| Thyroid ^{28, 29} | miR-221, miR-222, miR-146, miR-181b, miR-197, miR-346 | |
| Hepatocellular ^{28, 29} | miR-18, miR-224 | miR-199a, miR-195, miR-200a, miR-125a |
| Testicular ³⁰ | miR-372, miR-373 | |
| Pancreatic ²⁸⁻³⁰ | miR-221, miR-376a, miR301, miR-21, miR-24-2, miR-100, miR-103-1,2, miR-107, miR-125b-1 | miR-375 |
| Cholangiocarcinoma ²⁹ | miR-21, miR-141, miR-200b | |
| Prostate ^{30, 32-34} | let-7d, miR-195, miR-203 | miR-128a |
| Gastric ²⁸⁻³⁰ | miR-223, miR-21, miR-103-2 | miR-218-2 |
| Lung ^{13, 28-30} | mir-17-92 cluster, miR-17-5p | let-7 family |

Supplementary Data Figure 1.

miR-16 expression

(226 samples: breast cancer cases and controls)



MiR-16 expression in whole blood samples of all 226 participants. Systemic miR-16 is stably expressed across all samples and thus is a suitable reference gene for normalising RQ-PCR data in this study